Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish

DMM Disease Models and Mechanisms

Volumn 5, Issue 4, 2012, Pages 546-552

  Anastasaki, Corina ^a   Rauen, Katherine A ^b   Patton, E Elizabeth ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE;

ALLELE; ANIMAL TISSUE; ARTICLE; BODY HEIGHT; CARDIOFACIOCUTANEOUS SYNDROME; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRANIOFACIAL DEVELOPMENT; EMBRYO; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; GENE MUTATION; HEART DEVELOPMENT; MULTIPLE MALFORMATION SYNDROME; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ZEBRA FISH;

ANIMALS; BENZAMIDES; DIPHENYLAMINE; ECTODERMAL DYSPLASIA; EMBRYO, NONMAMMALIAN; FACIES; FAILURE TO THRIVE; HEART DEFECTS, CONGENITAL; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHENOTYPE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SMALL MOLECULE LIBRARIES; ZEBRAFISH;

DANIO RERIO;

EID: 84863494976     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.008672     Document Type: Article

References (29)

1. Anastasaki, C., Estep, A. L., Marais, R., Rauen, K. A. and Patton, E. E. (2009). Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors. Hum. Mol. Genet. 18, 2543-2554.
2. Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M. et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
3. Chen, P. C., Wakimoto, H., Conner, D., Araki, T., Yuan, T., Roberts, A., Seidman, C. E., Bronson, R., Neel, B. G., Seidman, J. G. et al. (2010). Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome-associated Sos1 mutation. J. Clin. Invest. 120, 4353-4365.
4. Crump, J. G., Maves, L., Lawson, N. D., Weinstein, B. M. and Kimmel, C. B. (2004). An essential role for Fgfs in endodermal pouch formation influences later craniofacial skeletal patterning. Development 131, 5703-5716. (Pubitemid 39625213)
5. Grzmil, M., Whiting, D., Maule, J., Anastasaki, C., Amatruda, J. F., Kelsh, R. N., Norbury, C. J. and Patton, E. E. (2007). The INT6 cancer gene and MEK signaling pathways converge during zebrafish development. PLoS ONE 2, e959.
6. Haura, E. B., Ricart, A. D., Larson, T. G., Stella, P. J., Bazhenova, L., Miller, V. A., Cohen, R. B., Eisenberg, P. D., Selaru, P., Wilner, K. D. et al. (2010). A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin. Cancer Res. 16, 2450-2457.
7. Ishizaki, H., Spitzer, M., Wildenhain, J., Anastasaki, C., Zeng, Z., Dolma, S., Shaw, M., Madsen, E., Gitlin, J., Marais, R. et al. (2010). Combined zebrafish-yeast chemical-genetic screens reveal gene-copper-nutrition interactions that modulate melanocyte pigmentation. Dis. Model. Mech. 3, 639-651.
8. Komisarczuk, A. Z., Topp, S., Stigloher, C., Kapsimali, M., Bally-Cuif, L. and Becker, T. S. (2008). Enhancer detection and developmental expression of zebrafish sprouty1, a member of the fgf8 synexpression group. Dev. Dyn. 237, 2594-2603.
9. Krens, S. F., He, S., Lamers, G. E., Meijer, A. H., Bakkers, J., Schmidt, T., Spaink, H. P. and Snaar-Jagalska, B. E. (2008). Distinct functions for ERK1 and ERK2 in cell migration processes during zebrafish gastrulation. Dev. Biol. 319, 370-383.
10. LoRusso, P. M., Krishnamurthi, S. S., Rinehart, J. J., Nabell, L. M., Malburg, L., Chapman, P. B., DePrimo, S. E., Bentivegna, S., Wilner, K. D., Tan, W. et al. (2010). Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin. Cancer Res. 16, 1924-1937.
11. Molina, G. A., Watkins, S. C. and Tsang, M. (2007). Generation of FGF reporter transgenic zebrafish and their utility in chemical screens. BMC Dev. Biol. 7, 62.
12. Pagani, M. R., Oishi, K., Gelb, B. D. and Zhong, Y. (2009). The phosphatase SHP2 regulates the spacing effect for long-term memory induction. Cell 139, 186-198.
13. Pratilas, C. A. and Solit, D. B. (2010). Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin. Cancer Res. 16, 3329-3334.
14. Rauen, K. A., Schoyer, L., McCormick, F., Lin, A. E., Allanson, J. E., Stevenson, D. A., Gripp, K. W., Neri, G., Carey, J. C., Legius, E. et al. (2010). Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am. J. Med. Genet. A 152, 4-24.
15. Rauen, K. A., Banerjee, A., Bishop, W. R., Lauchle, J. O., McCormick, F., McMahon, M., Melese, T., Munster, P. N., Nadaf, S., Packer, R. J. et al. (2011). Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am. J. Med. Genet. C 157, 136-146.
16. Roberts, A., Allanson, J., Jadico, S. K., Kavamura, M. I., Noonan, J., Opitz, J. M., Young, T. and Neri, G. (2006). The cardiofaciocutaneous syndrome. J. Med. Genet. 43, 833-842. (Pubitemid 44787108)
17. Rodriguez-Viciana, P., Tetsu, O., Tidyman, W. E., Estep, A. L., Conger, B. A., Cruz, M. S., McCormick, F. and Rauen, K. A. (2006). Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311, 1287-1290. (Pubitemid 43334718)
18. Runtuwene, V., van Eekelen, M., Overvoorde, J., Rehmann, H., Yntema, H. G., Nillesen, W. M., van Haeringen, A., van der Burgt, I., Burgering, B. and den Hertog, J. (2011). Noonan syndrome gain-of-function mutations in NRAS cause zebrafish gastrulation defects. Dis. Model. Mech. 4, 393-399.
19. Sebolt-Leopold, J. S. (2008). Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin. Cancer Res. 14, 3651-3656.
20. Senawong, T., Phuchareon, J., Ohara, O., McCormick, F., Rauen, K. A. and Tetsu, O. (2008). Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options. Hum. Mol. Genet. 17, 419-430.
21. Sharma, S. V. and Settleman, J. (2007). Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21, 3214-3231. (Pubitemid 350277749)
22. Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I. et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362. (Pubitemid 43128863)
23. Tidyman, W. E. and Rauen, K. A. (2009). The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr. Opin. Genet. Dev. 19, 230-236.
24. Urosevic, J., Sauzeau, V., Soto-Montenegro, M. L., Reig, S., Desco, M., Wright, E. M., Cañamero, M., Mulero, F., Ortega, S., Bustelo, X. R. et al. (2011). Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-faciocutaneous syndrome. Proc. Natl. Acad. Sci. USA 12, 5015-5020.
25. Walshe, J. and Mason, I. (2003). Fgf signalling is required for formation of cartilage in the head. Dev. Biol. 264, 522-536. (Pubitemid 37492973)
26. Wilkie, A. O. (2007). Cancer drugs to treat birth defects. Nat. Genet. 39, 1057-1059.
27. Wilson, Y. M., Richards, K. L., Ford-Perriss, M. L., Panthier, J. J. and Murphy, M. (2004). Neural crest cell lineage segregation in the mouse neural tube. Development 131, 6153-6162. (Pubitemid 40123928)
28. Wu, X., Simpson, J., Hong, J. H., Kim, K. H., Thavarajah, N. K., Backx, P. H., Neel, B. G. and Araki, T. (2011). MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J. Clin. Invest. 121, 1009-1025.
29. Yang, H., Higgins, B., Kolinsky, K., Packman, K., Go, Z., Iyer, R., Kolis, S., Zhao, S., Lee, R., Grippo, J. F. et al. (2010). RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70, 5518-5527.